AOD-9604 is a fifteen-residue piece of human growth hormone, and the interesting question is what a fragment can and cannot inherit from its parent. It corresponds to residues 176–191, the C-terminal region, with a disulphide bridge and a tyrosine added at the N-terminus. It is the clearest example in this catalogue of a design premise that recurs constantly: take the region associated with one activity and leave behind the region responsible for another.
The fragment idea
Human growth hormone is 191 residues, and its principal activities run through the growth hormone receptor. Dimerising that receptor requires a large, structured binding surface distributed across the molecule — not a feature a fifteen-residue fragment can reproduce.
The proposal behind AOD-9604 is that a distinct activity associated with the C-terminal region is separable from receptor-mediated activity, and that isolating the fragment therefore isolates one without the other. Whether that separation holds is the empirical question the compound exists to test. What can be said with confidence is the negative half: the fragment cannot act at the growth hormone receptor as the intact hormone does, because the structure required is absent.
| hGH | AOD-9604 | |
|---|---|---|
| Length | 191 residues | 15 residues + Tyr |
| Structure | Four-helix bundle, folded | Short, one disulphide bridge |
| GH receptor activity | Yes | Not by the same mechanism |
| IGF-1 induction | Yes | Not expected |
| Made by | Recombinant expression | Solid-phase synthesis |
Why can a fragment not act like the whole hormone?
Because receptor activation here is a structural event, not a sequence-recognition one. The growth hormone receptor is activated by a single hormone molecule binding two receptor copies through two separate surfaces, bringing them together. That requires a folded molecule presenting both surfaces at a fixed geometry. Fifteen residues cannot fold into that arrangement, and no amount of sequence identity substitutes for it. This is the general reason fragments do not inherit their parents' activities — it applies equally to TB-500 against thymosin β4, and to Semax against ACTH.
What is the tyrosine at the start for?
It is not part of the native hGH sequence. A tyrosine added at the N-terminus provides a residue that absorbs strongly at 280 nm, which makes the peptide quantifiable by ultraviolet absorbance — useful because a sequence with no aromatic residues is nearly invisible at that wavelength. It also historically provided a site for radioiodination in tracer studies. So the modification is analytical rather than pharmacological, which is worth knowing: it is there to make the molecule measurable, not to make it active.
The disulphide bridge
The fragment retains a cysteine pair forming an internal disulphide bridge, which closes the sequence into a loop. This matters more than it might appear.
The bridge is a structural feature, so the molecule has a defined conformation in a way most short peptides do not. It also means the compound is sensitive to reducing conditions: DTT, β-mercaptoethanol and other reducing agents will break the bridge, and the resulting linear peptide is a different molecule with the same mass. That last point is the awkward one — reduction is invisible to a mass measurement, so a certificate confirming identity by mass does not confirm the bridge is intact.
How would I know if the disulphide bridge had opened?
Not from the mass, which barely moves — two hydrogens. What does change is chromatographic behaviour: the reduced, linear form usually elutes at a different retention time from the closed loop, so an HPLC trace will show it as a separate peak even though a mass spectrometer reports the expected value. This is one of the clearer illustrations of why identity and purity answer different questions, and why a chromatogram is worth more than the figure derived from it. Practically: avoid reducing agents in buffers, and do not assume a correct mass means a correct molecule.
Can it form the wrong disulphide bridge?
With one cysteine pair, the intramolecular options are limited — but intermolecular ones are not. Two molecules can bridge to each other instead of each closing internally, producing a dimer with roughly double the mass and different behaviour. This is concentration-dependent, so a concentrated stock is more exposed than a dilute one, and it is the same chemistry that makes free cysteines a handling problem generally. Minimising air exposure and avoiding alkaline conditions, where thiol exchange runs fastest, is the practical answer — the general rules for bridged peptides apply with a single bridge too.
Reading its literature
Two cautions, both structural rather than about the findings themselves.
First, check whether a study used the fragment or intact growth hormone. The two are conflated in secondary sources with some regularity, and a result about the hormone tells you nothing reliable about the fragment.
Second, note that a considerable share of the published work comes from a small number of connected groups, over a period when the compound was in commercial development. That is not a reason to discount it, but it is a reason to ask whether anything has been replicated independently — the same question worth asking of BPC-157 and TB-500, and for the same reason. Volume of citations and weight of evidence diverge more than usual in this corner of the field.
Does AOD-9604 raise IGF-1 the way growth hormone does?
It would not be expected to, and that is the design intent rather than a shortcoming. IGF-1 induction is downstream of growth hormone receptor activation in the liver, and a fragment that cannot activate that receptor has no route to it. A study reporting IGF-1 changes from the fragment would be reporting something unexpected and worth scrutinising closely — either a mechanism nobody has described, or intact hormone contamination. The absence of that effect is what the fragment was for.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
